Clinical Trials
16 trialsNCT01789255 2018-07-24
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
Phase 2 Completed
NCT00381550 2015-01-06
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00387426 2014-05-28
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00008307 2014-01-06
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00008164 2013-12-18
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00335868 2013-12-18
PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00036712 2013-09-20
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004061 2013-06-26
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005618 2013-06-21
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00066599 2013-06-19
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00066417 2013-05-01
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003408 2013-03-26
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00627666 2013-03-26
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00054431 2013-01-23
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00806767 2011-05-17
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00740467 2010-01-28
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
National Cancer Institute (NCI)
Phase 2 Unknown